Products

Evagene

Uses AI

Fast pedigree drawing. Twenty-one published risk-model algorithms. A 1,900-entry catalogue. In the browser.

evagene.com Industry Software / Life Sciences & Biotech

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Sep 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Adrian Pickering
No social account linked
Launched
7mo ago
2026-04-17 · Est.

Traffic

Last 12 months
Monthly visitsData through Sep 2026 · Oct 2026 pending
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions

  • Launched on Product HuntLaunch

    Clinical-grade pedigree analysis, finally in your browser

    Apr 17 · 7mo agoLaunch page

Traffic sources

Sep 2026

Traffic breakdown

Channels

  • Direct39%
  • Organic Search31%
  • Referrals11%
  • Social6%
  • Other13%

Countries

  • United States100%

Search

Domain authority —Domain registered 2008-06-19

KeywordMonthly volume
pedigree maker1,580
cis regulatory dna elements240
pedigree symbols and their meanings130
evagene60
what can we see from a pedigree chart—

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-04-17

Key pages

Weekly snapshots
evagene.com/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Evagene get?
Vaneform estimates <5K website visits in 2026-09. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Evagene and what platforms does it support?
Evagene is catalogued under Life Sciences & Biotech: Fast pedigree drawing. Twenty-one published risk-model algorithms. A 1,900-entry catalogue. In the browser.. Supported platforms: Web.

Related products in this category

Industry Software / Life Sciences & Biotech

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.